Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $292.1252W HIGH $475.64
Volume
3.20 M
Value Traded
1.49 B
Short % Float
2.48%
Days to Cover
5.0
+3.91%Week
+15.5%1 Month
+19.34%3 Month
+41.22%6 Month
+33.74%5 Year
+98,606.32%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
251.64 B
EPS (TTM)
16.17
P/E Ratio
28.78
Ent. Value
300.40 B
Total Shares
540.63 M
Float Shares
539.40 M
Insiders
0.23%
Institutions
85.69%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
AMGN Catalyst Timeline
Dated clinical, regulatory and corporate events for Amgen Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Amgen Inc.
2438Total events
19Upcoming
971Tier-1 (high impact)
2010 to 2036Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseCorporate
NORD and Amgen launch 14-month Learning Collaborative pilot across Rare Disease Centers of Excellence
IgG4-Related Disease (IgG4-RD) and Thyroid Eye Disease (TED)source ↗
▲Topline ReadoutIMDELLTRAApprovedClinical Data
Interim Phase 3 DeLLphi-305 results: IMDELLTRA + IMFINZI reduced risk of death by 58% in 1L maintenance ES-SCLC
extensive stage small cell lung cancer (ES-SCLC)source ↗
▲Long Term DataIMDELLTRAApprovedClinical Data
DeLLphi-303 updated data: median OS 37.9 months in 1L maintenance with IMDELLTRA plus anti-PD-L1
extensive stage small cell lung cancer (ES-SCLC)source ↗
▲PublicationIMDELLTRAApprovedPresentation
DeLLphi-305 results simultaneously published in The New England Journal of Medicine
extensive stage small cell lung cancer (ES-SCLC)source ↗
▲Late-BreakerIMDELLTRAApprovedPresentation
DeLLphi-305 presented as late-breaker (LBA3) in ESMO 2026 Presidential Symposium
extensive stage small cell lung cancer (ES-SCLC)source ↗
▲Primary Endpoint MetIMDELLTRAApprovedClinical Data
DeLLphi-305 met primary OS endpoint with 58% reduction in risk of death
extensive stage small cell lung cancer (ES-SCLC)source ↗
▲Poster PresentationIMDELLTRAApprovedPresentation
DeLLphi-303 updated OS data presented as poster (3821P) at ESMO 2026
extensive stage small cell lung cancer (ES-SCLC)source ↗
▲Oral PresentationIMDELLTRAApprovedPresentation
DeLLphi-304 updated data presented as oral (3808O) at ESMO 2026
previously treated extensive stage small cell lung cancer (ES-SCLC)source ↗
▲Full ResultsTEZSPIREApprovedClinical Data
Full CROSSING Phase 3 results in EoE announced
eosinophilic esophagitis (EoE)source ↗
▲Primary Endpoint MetTEZSPIREApprovedClinical Data
CROSSING co-primary endpoints met at week 24
eosinophilic esophagitis (EoE)source ↗
▲Topline ReadoutDazodalibepClinical Data
Positive topline Phase 3 results for dazodalibep in moderate-to-severe systemic Sjögren's disease
moderate-to-severe systemic Sjögren's diseasesource ↗
▲Primary Endpoint MetDazodalibepClinical Data
OASIZ 301 met primary endpoint of change from baseline in ESSDAI at Week 48
moderate-to-severe systemic Sjögren's diseasesource ↗
▲Label ExpansionIMDELLTRAApprovedFDA Decision
FDA approves reduced monitoring time for first two doses of IMDELLTRA
extensive-stage small cell lung cancer (ES-SCLC)source ↗
▲Primary Endpoint MetIMDELLTRAApprovedClinical Data
IMDELLTRA plus IMFINZI met primary overall survival endpoint in first-line ES-SCLC
first-line extensive stage small cell lung cancersource ↗
▲Secondary Endpoint DataIMDELLTRAApprovedClinical Data
DeLLphi-305 met secondary PFS and ORR endpoints
first-line extensive stage small cell lung cancersource ↗
▲Oral PresentationRepathaApprovedPresentation
Late-breaking presentation of VESALIUS-CV mortality analysis at ESC Congress 2026
high-risk primary preventionsource ↗
▲PublicationRepathaApprovedPresentation
VESALIUS-CV mortality analysis published in Circulation
high-risk primary preventionsource ↗
●Poster PresentationRepathaApprovedPresentation
Poster on Lp(a) testing from CVMOBIUS2 Registry
atherosclerotic cardiovascular diseasesource ↗
▲Oral PresentationRepathaApprovedPresentation
Presentation of total CV events analysis
high-risk primary preventionsource ↗
●Poster PresentationRepathaApprovedPresentation
Poster on lipid management in coronary artery disease
coronary artery diseasesource ↗
▲Oral PresentationRepathaApprovedPresentation
Presentation of first MI risk analysis
high-risk primary preventionsource ↗
▲Topline ReadoutTEZSPIREApprovedClinical Data
TEZSPIRE demonstrates positive Phase 3 results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
eosinophilic esophagitissource ↗
●Quarterly UpdateTAVNEOSApprovedCorporate
Amgen continues engagement with FDA regarding TAVNEOS
▲EU ApprovalRepathaApprovedEx-US Regulatory
European Commission approved expanded indication for Repatha
established or high risk for ASCVDsource ↗
▲CHMP Positive OpinionRepathaApprovedEx-US Regulatory
CHMP positive opinion for broader use of Repatha
cardiovascular risk reduction in adults with established atherosclerotic cardiovascular disease or at high risksource ↗
▲CHMP Positive OpinionRepathaApprovedEx-US Regulatory
CHMP positive opinion for broader use of Repatha to reduce risk of first heart attack or stroke
cardiovascular risk reduction in adults with established atherosclerotic cardiovascular disease or at high risksource ↗
▲CHMP Positive OpinionRepathaApprovedEx-US Regulatory
CHMP adopted positive opinion for Repatha to reduce cardiovascular risk in adults with established or at high risk for ASCVD
atherosclerotic cardiovascular diseasesource ↗
▲IP Litigation RulingIP / Competition
Jury finds Amgen willfully infringed Harbour's Grosveld Patent, awards $20.2M damages
◆Oral PresentationPresentation
Amgen to present at Goldman Sachs 47th Annual Global Healthcare Conference
▲Oral PresentationRepathaApprovedPresentation
VESALIUS-CV subgroup results for Repatha in high-risk diabetes patients presented at ADA 2026
high-risk diabetes with elevated LDL-Csource ↗
●Oral PresentationPresentation
Real-world evidence studies on GLP-1 therapy persistence and adherence presented at ADA 2026
obesity and diabetessource ↗
▲EU ApprovalIMDYLLTRAApprovedEx-US Regulatory
EC approval of IMDYLLTRA for advanced SCLC
мелкоклеточный рак легкого на запущенной стадииsource ↗
◆Oral PresentationUPLIZNAApprovedPresentation
Natural History of IgG4-RD: Patterns of Organ Involvement and Flare-associated Biomarker Changes in the Phase 3 MITIGATE Trial (Abstract #OP052) oral presentation at EULAR 2026
IgG4-related diseasesource ↗
◆Poster PresentationUPLIZNAApprovedPresentation
Long-term Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Primary Results from Year 1 of the Open-Label Period of the Phase 3 MITIGATE Trial (Abstract #POS0440) poster presentation at EULAR 2026
IgG4-related diseasesource ↗
◆Poster PresentationTAVNEOSApprovedPresentation
Real-world evidence from AQUARIUS analyses (Abstracts #POS0135 and #POS0867) poster presentations at EULAR 2026
ANCA-associated vasculitissource ↗
▲EU ApprovalIMDYLLTRAApprovedEx-US Regulatory
European Commission grants marketing authorization for IMDYLLTRA as monotherapy for ES-SCLC
extensive-stage small cell lung cancersource ↗
◆Oral PresentationPresentation
Amgen presentation at Bank of America Merrill Lynch Global Healthcare Conference
▲Trial InitiationMariTideTrial
MARITIME-2 EXTENSION Phase 3 trial initiated for MariTide
obesitysource ↗
▲Trial InitiationOlpasiranTrial
Phase 3 OCEAN(a)-Outcomes trial initiated for olpasiran
cardiovascular diseasesource ↗
▲Trial InitiationUPLIZNAApprovedTrial
Phase 3 MITIGATE trial initiated for UPLIZNA in IgG4-RD
IgG4-related diseasesource ↗
▲Trial InitiationTEPEZZAApprovedTrial
Phase 3 trial initiated for TEPEZZA in chronic TED
chronic thyroid eye diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How AMGN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-24 | tarlatamab-dlle (IMDELLTRA) plus durvalumab (IMFINZI) | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
37
Drugs Scored
rNPV / MCap
Top Drug
Top 1%
Large Pharma(rank 1 of 674)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Prolia | |||
| Repatha | |||
| EVENITY | |||
| Otezla | |||
| TEPEZZA | |||
| ENBREL | |||
| XGEVA | |||
| BLINCYTO | |||
| Nplate | |||
| TEZSPIRE | |||
| KRYSTEXXA | |||
| KYPROLIS |
Top 12 of 14 product lines shown.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Maridebart cafraglutide Small moleculeNCT07226765 | Obstructive Sleep Apnea | Phase 3 | ACTIVE NOT_RECRUITING | 250 | Sep 13, 2028 | ||||||
| Maridebart cafraglutide Small moleculeNCT07160257 | Type 2 Diabetes Mellitus | Phase 3 | ACTIVE NOT_RECRUITING | 1,765 | Mar 4, 2027 | ||||||
| Maridebart cafraglutide Small moleculeNCT06858878 | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | Phase 3 | ACTIVE NOT_RECRUITING | 1,105 | Apr 16, 2027 | ||||||
| Maridebart cafraglutide Small moleculeNCT06987695 | Obesity Disease | Phase 3 | ACTIVE NOT_RECRUITING | 279 | Jul 21, 2027 | ||||||
| Maridebart cafraglutide Small moleculeNCT06858839 | Obesity | Phase 3 | ACTIVE NOT_RECRUITING | 9,205 | Apr 16, 2027 | ||||||
| Maridebart cafraglutide Small moleculeNCT07575399 | Obesity or Overweight | Phase 3 | RECRUITING | 300 | Feb 28, 2028 | ||||||
| Maridebart cafraglutide Small moleculeNCT07037459 | Heart Failure With Preserved Ejection Fraction | Phase 3 | RECRUITING | 5,056 | Sep 29, 2030 | ||||||
| Maridebart cafraglutide Small moleculeNCT07037433 | Atherosclerotic Cardiovascular Disease | Phase 3 | ACTIVE NOT_RECRUITING | 12,800 | Sep 29, 2030 | ||||||
| Maridebart cafraglutide Small moleculeNCT07441252 | Overweight or Obesity and Elevated Liver Fat | Phase 2 | ACTIVE NOT_RECRUITING | 180 | Nov 17, 2027 | ||||||
| Maridebart cafraglutide Small moleculeNCT07523711 | Overweight | Phase 1 | ACTIVE NOT_RECRUITING | 818 | Nov 18, 2026 | ||||||
| Tarlatamab Monoclonal antibodyMarketedNCT05361395 | Extensive Stage Small Cell Lung Cancer | Approved | ACTIVE NOT_RECRUITING | 1,379 | May 30, 2030 | ||||||
| Tarlatamab Monoclonal antibodyMarketedNCT06898957 | Small Cell Lung Cancer | Approved | ACTIVE NOT_RECRUITING | 1,723 | Jun 23, 2031 | ||||||
| Tarlatamab Monoclonal antibodyNCT06117774 | Limited Stage Small Cell Lung Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 834 | Apr 20, 2030 | ||||||
| Tarlatamab Monoclonal antibodyMarketedNCT07423585 | Extensive Stage Lung Small Cell Carcinoma | Approved | RECRUITING | 39 | Dec 31, 2027 | ||||||
| Tarlatamab Monoclonal antibodyMarketedNCT05060016 | Relapsed/Refractory Small Cell Lung Cancer | Approved | ACTIVE NOT_RECRUITING | 222 | Dec 30, 2027 | ||||||
| Tarlatamab Monoclonal antibodyMarketedNCT03319940 | Small Cell Lung Carcinoma | Approved | ACTIVE NOT_RECRUITING | 269 | Dec 31, 2027 | ||||||
| Olpasiran RNA therapyNCT05581303 | Atherosclerotic Cardiovascular Disease | Phase 3 | ACTIVE NOT_RECRUITING | 7,297 | Mar 31, 2028 | ||||||
| ABP 692 Small moleculeNCT06700343 | Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 3 | ACTIVE NOT_RECRUITING | 152 | Oct 4, 2027 | ||||||
| ABP 234 Small moleculeNCT06311721 | Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 315 | Apr 24, 2028 | ||||||
| ABP 234 Small moleculeNCT06430866 | Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) | Phase 3 | ACTIVE NOT_RECRUITING | 163 | Dec 14, 2026 | ||||||
| AMG 127 Small moleculeNCT07590193 | Diabetes Mellitus, Type 2 | Phase 1 | RECRUITING | 162 | Oct 2, 2027 | ||||||
| ABP 206 Small moleculeNCT06054555 | Melanoma | Phase 3 | ACTIVE NOT_RECRUITING | 889 | Jan 25, 2028 | ||||||
| AMG 691 Small moleculeNCT06637371 | Asthma | Phase 1 | ACTIVE NOT_RECRUITING | 21 | Apr 10, 2027 | ||||||
| Inebilizumab Monoclonal antibodyNCT07598825 | Autoimmune Hepatitis | Phase 3 | RECRUITING | 180 | Feb 11, 2034 | ||||||
| Inebilizumab Monoclonal antibodyNCT04540497 | IgG4 Related Disease | Phase 3 | ACTIVE NOT_RECRUITING | 135 | Oct 31, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every AMGN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| dazodalibep | Sjögren's disease | Phase 3 | 2026-10-27 | ESSDAI score change 4w: -5.6; ESSDAI score change 12w: -5.2; ESSDAI score change placebo: -3.8; ESSPRI dryness score change: -2.50; ESSPRI dryness score change placebo: -1.33; DASPRI dryness score change: -1.98; DASPRI dryness score change placebo: -1.05Read More | AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Khosla RachnaOfficer (SVP, Business Development) | Option | 1,252 7,656 held | $162.60 | 08/13/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AMGN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 0.3 % | 14.04 M | 39.90 K | -9.73% ( -4.30 K) |
Ownership Trends
AMGN Short Interest
Shares sold short, counted twice a month.
2.48%
Short % of Float
of tradable shares sold short
13.4M
Shares Sold Short
-4.6% vs prior count
5.0 Moderate
Days to Cover
trading days of normal volume to buy every short share back
2.7M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-06 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AMGN ranks across every disease it competes in
Competitive Position is a premium feature
See how AMGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAMGN News
AMGNAMGEN ANNOUNCES WEBCAST OF 2026 THIRD QUARTER FINANCIAL RESULTS
Amgen will announce its third quarter 2026 financial results on November 3, 2026. Following the announcement, a conference call will take place at 4:30 p.m. ET, featuring CEO Robert A. Bradway and senior management. The call will be broadcast live and available for replay on Amgen's website.
Read more →AMGNAMGEN ANNOUNCES 2026 FOURTH QUARTER DIVIDEND
Amgen announced a quarterly dividend of $2.52 per share for Q4 2026. This dividend will be paid on December 11, 2026, to stockholders of record as of November 20, 2026. The company continues to be recognized for its innovation in the biotechnology sector.
Read more →AMGNAMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026
Amgen announced it will present new data on autoimmune diseases at ACR Convergence 2026. Key findings include significant improvements in systemic disease activity and dryness in Sjögren's disease patients treated with dazodalibep. Additionally, long-term data for UPLIZNA in IgG4-related disease will be shared, highlighting Amgen's dedication to rare diseases.
Read more →AMGNNORD and Amgen Launch Learning Collaborative to Improve Rare Disease Diagnosis and Care
NORD and Amgen have launched a Learning Collaborative to enhance the diagnosis and care of rare autoimmune diseases, specifically IgG4-Related Disease and Thyroid Eye Disease. This 14-month pilot program will involve 5 to 8 institutions working together to identify and address challenges in care coordination and diagnosis. The initiative aims to generate insights applicable to other rare diseases as well.
Read more →AMGNAMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORS
Amgen appointed David W. Gibbs to its Board of Directors, effective immediately. Gibbs, former CEO of Yum! Brands, will serve on the Audit and Compensation Committees. His leadership experience and expertise in customer relations are expected to benefit Amgen's future product launches and innovations.
Read more →AMGNIMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
Amgen announced that IMDELLTRA combined with IMFINZI significantly reduced the risk of death by 58% in extensive stage small cell lung cancer patients. Nearly 80% of patients were alive at one year, compared to 53% with IMFINZI alone. The median overall survival reached 21.1 months, marking a substantial improvement in treatment outcomes. These results were presented at the ESMO Congress 2026.
Read more →AMGNAMGEN FOUNDATION TOPS $75 MILLION IN HANDS-ON BIOTECHNOLOGY EDUCATION, REACHING 100,000 STUDENTS A YEAR
The Amgen Foundation announced a $13.4 million commitment to the Amgen Biotech Experience, extending the program through the 2027-28 school year. This initiative provides biotechnology education to over 100,000 students annually, with a total of 1.25 million students served since its inception. The program aims to enhance STEM education in schools, particularly those facing resource challenges.
Read more →AMGNAMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026
Amgen will host a webcast on October 24, 2026, during the ESMO 2026 Congress. Executives Murdo Gordon and Jean-Charles Soria will discuss the oncology portfolio and selected data. The event is open to investors and media. It will be archived for 30 days.
Read more →AMGNTEZSPIRE® DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS
Amgen and AstraZeneca announced positive results from the Phase 3 CROSSING trial for TEZSPIRE in treating eosinophilic esophagitis (EoE). The trial demonstrated significant improvements in histologic remission and symptom severity at both 24 and 52 weeks. TEZSPIRE achieved remission in 64.8% to 68.9% of patients, outperforming placebo significantly. These findings suggest TEZSPIRE could be an important new treatment option for patients with uncontrolled EoE.
Read more →AMGNAMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE
Amgen announced positive topline results from the Phase 3 OASIZ 301 study of dazodalibep for moderate-to-severe Sjögren's disease. The study met its primary endpoint, showing significant improvement in systemic disease activity at Week 48. This marks a potential breakthrough for patients, as there are currently no FDA-approved treatments for this debilitating autoimmune disease.
Read more →AMGNFDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®
Amgen announced that the FDA has approved a significant reduction in the monitoring time required for the first two doses of IMDELLTRA (tarlatamab-dlle) from 22-24 hours to 6-8 hours. This change aims to enhance patient access to treatment for extensive-stage small cell lung cancer by allowing for less time spent in healthcare settings. Follow-up assessments will still be conducted the day after each of the initial doses.
Read more →AMGNAMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
Amgen will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. Key executives, including Jay Bradner and Thomas Dittrich, will discuss the company's developments. The presentation will be available via webcast for the public and investors, with an archive accessible for 90 days post-event.
Read more →AMGN▼ -10.1%on this newsshared move
IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
Amgen announced that its Phase 3 DeLLphi-305 study met its primary endpoint. The trial showed a statistically significant improvement in overall survival for patients with extensive stage small cell lung cancer. IMDELLTRA combined with durvalumab outperformed durvalumab alone as a first-line maintenance treatment. The drug also improved progression-free survival and objective response rates in the study.
Read more →AMGNAMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE
Amgen will present at the 2026 Wells Fargo Healthcare Conference on September 10, 2026. Key executives, including the CFO and CMO, will participate in the presentation. The event will be available via a live webcast, allowing media and investors to access the information. The webcast will also be archived for later viewing.
Read more →AMGNAMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
Amgen announced that Repatha (evolocumab) significantly reduces the risk of death in high-risk adults without prior cardiovascular events, as shown in the Phase 3 VESALIUS-CV trial. The study, which involved over 12,000 patients, demonstrated a 20% reduction in overall mortality. These findings highlight the importance of early and intensive LDL-C lowering in preventing cardiovascular morbidity and mortality.
Read more →AMGNTEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS
Amgen and AstraZeneca announced positive Phase 3 results for TEZSPIRE in treating eosinophilic esophagitis. The drug met its co-primary endpoints for histologic remission and dysphagia improvement at week 24. These benefits remained sustained through week 52 in the CROSSING trial. The safety profile was consistent with previous indications for the treatment.
Read more →AMGNAMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
Amgen reported strong financial results for Q2 2026, with total revenues rising 10% to $10.1 billion, driven by significant growth in key products. GAAP EPS increased 65% to $4.37, reflecting higher revenues. However, some products, like Prolia, experienced declines in sales, indicating challenges in certain segments. The company remains optimistic about future growth prospects, particularly with ongoing Phase 3 trials.
Read more →AMGNFIRST AMGEN SCHOLARS PROGRAM IN INDIA LAUNCHES AT IIIT HYDERABAD
Amgen has launched its first Scholars Program in India at IIIT Hyderabad, aimed at inspiring future scientific innovators. The program will support 10 undergraduate scholars from various countries, focusing on AI and machine learning applications in healthcare and drug discovery. This initiative reflects Amgen's commitment to advancing science education and fostering collaboration in the region.
Read more →AMGNAMGEN ANNOUNCES 2026 THIRD QUARTER DIVIDEND
Amgen announced a dividend of $2.52 per share for the third quarter of 2026, payable on September 11, 2026. This dividend reflects the company's strong financial position and commitment to returning value to shareholders. The announcement highlights Amgen's ongoing innovation in biotechnology and its significant role in the industry.
Read more →About Amgen Inc.
HeadquartersONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320
Founded1980
BIOPHARMAWATCH ELITE PLUS
Trade the next AMGN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime